1 July 2023 in Turkish Archives of Pediatrics
Objective: Ventricular extrasystole is one of the most common rhythm disorders in children, and almost all of them are characterized by normal cardiac functions without structural cardiac abnormalities. The aim of this study was to assess the clinical course of ventricular extrasystole in children who did not have cardiac structural abnormalities. Materials and Methods: This retrospective study analyzed 24-hour rhythm Holter recordings performed in our clinic in children. Patients diagnosed with isolated ventricular extrasystole in Holter records and without structural heart disease on echocardiography were included in the evaluation. Results: A total of 20 160 Holter results were evaluated in the study, and 226 patients (male; 66%) met the criteria. The mean follow-up time was 8.7 ± 3.2 years. While 81.8% of the patients were asymptomatic, the most common symptom was palpitation and 5 patients had syncope. Of the patients, 72 (31.8%) received medical therapy. Beta-blockers were the most often pre- scribed medication. Cardiomyopathy did not develop in any of the patients during the follow- up period. A partial reduction in the frequency of ventricular extrasystole was observed in 42% of the patients, while complete recovery was observed in 22%. Conclusion: Ventricular extrasystole in children generally has a good prognosis; most of them are asymptomatic, and the rates of spontaneous regression over time are quite high, regard- less of the origin. Cite this article as: Uysal F, Özalp S, Genç A, Akça T, Türkmen H, Bostan OM. Ventricular extrasystole in children: Single-center experience. Turk Arch Pediatr. 2023;58(4):395-400.
26 March 2026 in Uludağ Üniversitesi Tıp Fakültesi Dergisi
The survival outcomes of cancer patients exposed to Coronavirus Disease 2019 (COVID-19), the duration required to resume oncological treatment, and the subsequent course of their malignancy remain areas with limited data. This retrospective study evaluated 128 cancer patients hospitalized for COVID-19 treatment between April 2020 and October 2023. Of the cohort, 39.8% were women and 60.2% were men. Findings revealed that patients with metastatic lung involvement faced a 3.34-fold increased risk of death during the acute infection. In the post-COVID survival cohort, multivariate analysis indicated that younger age, higher hemoglobin levels, higher systemic inflammatory index, lower pan-immune inflammation value, and absence of active cancer were associated with longer survival. Additionally, vaccine-related survival differences were observed; however, these findings should be interpreted cautiously as they likely reflect confounding factors such as prioritizing high-risk patients for certain vaccine types rather than a direct causal relationship. Notably, while treatment delays were common among patients with disease progression, these delays did not result in a statistically significant difference in overall survival during the long-term follow-up.